SOT is effective at treating cancer in 77% of patients
A newly published study by RGCC scientists has found that cancer patients treated with the highly targeted supportive oligonucleotide therapy (SOT) showed benefits in 77% of cases.
SOT is an advanced, personalized form of cancer treatment that disrupts how cancer cells replicate or survive.
A new paper published in the Vivo journal finds evidence that SOTs effectively target and kill cancer cells on their own.
Our research team is optimistic about the impact of their findings.